导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.07% | 1922/4773 |
| 近一周 | -0.04% | 879/5465 |
| 近一月 | 5.01% | 76/5421 |
| 近一季 | 5.79% | 291/5231 |
| 近半年 | 5.19% | 812/4920 |
| 近一年 | 4.09% | 1925/4394 |
| 近两年 | 39.79% | 1913/2954 |
| 近三年 | 48.88% | 579/2253 |
| 成立以来 | 52.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.74% 2888/4961 |
-7.93% 3817/5312 |
- - |
- - |
| 2025 | 10.90% 2782/4813 |
2.63% 1305/3635 |
11.63% 147/4076 |
-8.33% 4029/4524 |
5.60% 422/4813 |
| 2024 | 39.38% 25/3463 |
10.01% 84/2808 |
6.78% 132/3014 |
12.43% 2349/3129 |
5.54% 593/3463 |
| 2023 | -2.55% 587/2656 |
-2.51% 2002/2280 |
1.59% 209/2385 |
4.95% 109/2515 |
-6.25% 1689/2655 |
| 2022 | -4.31% 90/2207 |
2.26% 63/1919 |
-1.33% 1710/2016 |
-8.18% 178/2113 |
3.29% 728/2208 |
| 2021 | 0.31% 716/1822 |
10.12% 49/1255 |
-1.99% 1186/1330 |
-6.60% 966/1466 |
-0.49% 1244/1822 |
| 2020 | - - |
- - |
- - |
- - |
10.91% 575/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证银行ETF联接(LOF)C VS. 长安沪深300非周期A(740101) |